Hybridization News and Research

RSS

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

RainDance Technologies launches ASDSeq and XSeq Research Screening Panels

RainDance Technologies, Inc., today announced the commercial availability of the ASDSeq™ and XSeq™ Research Screening Panels. Developed in collaboration with Emory University and Greenwood Genetic Center, the two comprehensive panels enable researchers to simultaneously interrogate key genes known to be linked to X-chromosome disorders and syndromic forms of Autism Spectrum Disorder (ASD) using next-generation sequencing.

18 Mar 2011

New tool for studying microRNA expression in zebrafish

A new research tool for studying microRNA expression in zebrafish will help researchers study the effects of miRNA on the early development of this model organism and better understand developmental and disease mechanisms in humans, as described in Zebrafish, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Mar 2011

Caris Life Sciences to highlight new approaches for gynecologic cancers at SGO 2011 conference

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, today announced highlights from the company's upcoming symposium, "Using Biomarker Expression to Guide Therapy: An Evidence-Based Approach for Gynecologic Cancers," at the Society of Gynecologic Oncologists 2011 Annual Meeting on Women's Cancer in Orlando, FL on March 6.

5 Mar 2011

New rapid and inexpensive test can effectively identify never-smoking group with lung adenocarcinoma

An inexpensive and rapid testing method can effectively identify a sub-group of never-smoking lung cancer patients whose tumors express a molecule associated with increased risk of disease progression or recurrence, US researchers have found.

25 Feb 2011

New technique reveals spatial structure of microbial community

Like people in cities, microbes often live in complex communities that contain many different microbial types. Also like us, microbes tend to gravitate to and "hang out" with certain other types in their community, more than with the rest. And sometimes, when opportunities arise, they move to more favorable locations.

15 Feb 2011

Exiqon launches new Hi-Power microRNA labeling kits

Exiqon, a leading supplier of high-value gene expression analysis products, today announced the launch of the 3rd generation of miRCURY LNA microRNA Labeling Kit called Hi-Power for labeling of microRNAs for downstream hybridization to microRNA arrays.

24 Jan 2011

Key findings on plasma cell disorders to be presented at American Society of Hematology Annual Meeting

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic services, announced that Dr. Raul Braylan, Hematopathologist and Clinical Medical Director of Hematopathology Services, will present key findings related to plasma cell disorders at the upcoming 52nd Annual Meeting and Exposition of the American Society of Hematology.

4 Dec 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

Grant adds PTR-35 360° vertical rotator to bio product range

Grant Instruments, a world-renowned supplier of scientific, life sciences and data acquisition products, has introduced a variable speed, variable angle 360º vertical rotator combining three mixing functions - vertical rotation, reciprocation and vibration - into one easy-to-use and highly versatile compact unit.

23 Nov 2010

Exiqon publishes clinical study data on colon cancer

Exiqon A/S today published data from a clinical study that stratifies colon cancer patients into groups of high, medium and low chances of survival which may prove useful for optimizing the treatment of each individual cancer patient.

14 Nov 2010

CombiMatrix receives $488,958 grant under QTDP program

CombiMatrix Corporation a molecular diagnostics company with a focus on DNA-based clinical diagnostic testing services for oncology and pre-and postnatal developmental disorders, announced today the award of $488,958 under the Internal Revenue Service's Section 48D for Qualifying Therapeutic Discovery Projects.

4 Nov 2010

Agilent announces solution for exon analysis based on SurePrint G3 Exon Microarrays

Agilent Technologies Inc. today announced a solution for exon analysis based on SurePrint G3 Exon Microarrays. The solution provides a major expansion of Agilent's portfolio of gene expression reagents, microarrays and bioinformatics systems. This new system, available in mid-November, enables researchers to examine alternately expressed exons according to recently updated content, providing a global picture of RNA expression.

4 Nov 2010

Allen Institute releases new data and tools for exploring genes at work in human brain

The Allen Institute for Brain Science announced today its twentieth public data release, which includes new data and tools for exploring genes at work in the human brain. In addition to expanding and enhancing the Allen Human Brain Atlas, the Allen Institute launched two new human brain resources: the Ivy Glioblastoma Atlas Project and the NIMH Transcriptional Atlas of Human Brain Development.

3 Nov 2010

New Ovation systems improve nucleic acid extraction from FFPE tissue samples

NuGEN Technologies, the provider of innovative RNA and DNA sample preparation solutions for genomic analysis, today announced the availability of the Ovation WGA FFPE System and the Ovation RNA-Seq FFPE System. These are the first commercially available products designed specifically to enable researchers to utilize next-generation sequencing (NGS) technologies to analyze nucleic acids extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

3 Nov 2010

New algebraic model of DNA hybridization to measure cellular behavior

Researchers at New York University's Courant Institute of Mathematical Sciences have developed a novel algebraic model of DNA "hybridization," a process central to most biotechnology devices that monitor changes in cell's gene expression or characterize a cell's genome.

2 Nov 2010

Journal of Clinical Oncology publishes IPI-504 Phase 2 study results

Infinity Pharmaceuticals, Inc. announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology.

15 Oct 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Exiqon introduces on-line microRNA qPCR assay design software

Exiqon A/S, a leading supplier of high-value gene expression analysis products, today announced the extension of the miRCURY LNA microRNA PCR product line with the launch of a novel bioinformatics software for the design of custom qPCR assays for microRNA quantification.

12 Oct 2010

Triple-negative breast cancer patients may have unique biomarker to receive targeted therapy: Research

Patients with triple negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010